Fig. 5
![Fig. 5](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12951-022-01565-9/MediaObjects/12951_2022_1565_Fig5_HTML.png)
Immune response of CS@P together with laser and PD-L1 in vivo. a Schematic diagram of the model and therapeutic schedule of primary and distant H22 tumor model. b Primary tumor growth tendency of H22 tumor-bearing mice with various treatments. Tumor sizes were normalized to initial sizes. Error bars stand for ± SD (n = 6). c Primary tumor growth curves in the H22 tumor-bearing BALB/c mice (n = 6). d Representative flow cytometry plots showing different groups of T cells in primary tumors (gated on CD3+ T cells) after indicated treatments. e The Treg flow cytometry analysis in primary tumors after various treatments. f Representative flow cytometry plots showing matured DC cells in primary tumors after various treatments. g Immunohistochemical staining of NR2F6 and PD-L1 in primary tumor sections (top). H&E and TUNEL examination of tumor sections (bottom). Scale bar: 100 µm. *P < 0.05, **P < 0.01, and ***P < 0.001